

[Levodopa + carbidopa](#)

Essential medicine status

Section:

[5. Medicines for neurological disorders 5.1. Medicines for central nervous system disorders 5.1.3. Medicines for parkinsonism](#)

ATC codes: [N04BA02](#)

Indication

Parkinson disease ICD11 code: [8A00.0Z](#)

INN

Levodopa + carbidopa

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid: 100 mg + 10 mg tablet ; 250 mg + 25 mg tablet ; 100 mg + 25 mg tablet

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 2003 ([TRS 920](#))

Changed in 2013 ([TRS 985](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[levodopa + benserazide](#) (ATC codes: [N04BA02](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Levodopa + carbidopa](#)

DrugBank

[Levodopa](#),

[Carbidopa](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended benserazide be specified as a therapeutic alternative for the carbidopa component under the square box listing for levodopa + carbidopa on the EML.